Lyell Immunopharma Inc (LYEL NASDAQ) stock market data APIs
$12.2107
0.47(3.8%)
as of September 17, 2025
Try our APIs with
free plan!
Lyell Immunopharma Inc Financial Data Overview
Price chart is built with
Anychart
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company develops therapies using various approaches, such as c-Jun overexpression and NR4A3 gene knockout, to endow functional resistance to exhaustion; Epi-R to generate population of stem-like T cells with reduced exhaustion and improved proliferation and antitumor activity; CD62L positive enrichment to generate CAR T cells with enhanced antitumor activity; and Stim-R, a proprietary synthetic-cell mimetic. It is also developing IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product candidate that is in Phase 1/2 clinical development for the treatment of patients with aggressive relapsed/refractory large B-cell non-Hodgkin lymphoma; and solid tumors program which is in preclinical trial targeting solid tumor indications. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Prev. Close
12.2107
Open
12.6759
High
13.1548
Low
11.8803
52 wk Range
7.65-32
Market Cap
236 M
Shares Outstanding
19 211 K
Revenue
60 000
EPS
-2.89
Beta
-0.2
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Lyell Immunopharma Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Lyell Immunopharma Inc data using free add-ons & libraries
Get Lyell Immunopharma Inc Fundamental Data
Lyell Immunopharma Inc Fundamental data includes:
- Net Revenue: 60 000
- EBITDA: -194 868 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-06
- EPS/Forecast: -0.1633
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Lyell Immunopharma Inc News
New
Lyell Immunopharma CEO Seely sells shares worth $8k
Lyell Immunopharma (NASDAQ:LYEL) President and CEO Lynn Seely sold a total of 797 shares of common stock on August 11 and 12, 2025. The sales, which covered tax withholding obligations from vested res...
Lyell Immunopharma Inc (NASDAQ:LYEL) Reports Q2 2025 Earnings Beat with Clinical Progress on LYL314
LYELL IMMUNOPHARMA INC (NASDAQ:LYEL [https://www.chartmill.com/stock/quote/LYEL]) REPORTS Q2 2025 EARNINGS: NARROWER LOSS THAN EXPECTED, CLINICAL PROGRESS IN FOCUS Lyell Immunopharma Inc released its...
Lyell Immunopharma reports Q2 results
* Lyell Immunopharma press release [https://seekingalpha.com/pr/20198605-lyell-immunopharma-reports-business-highlights-and-financial-results-for-the-second-quarter] (NASDAQ:LYEL [https://seekingalp...
Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2025
Presented positive new clinical data demonstrating high rates of durable complete responses from the Phase 1/2 trial of LYL314 for the treatment of aggressive large B-cell lymphomaInitiated the PiNACL...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
